Post

Merck, Moderna say melanoma vaccine meets goals in large trial reut.rs/4zqdji1

reut.rsMerck, Moderna say melanoma vaccine meets goals in large trialMerck and Moderna said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced ‌skin cancer recurrence and spread compared with Keytruda alone, the first positive late-stage trial results for an mRNA cancer vaccine.

19/8/26, 11:05 am19 reposts49 likes

@pauldu.bsky.social

Despite the wanton ignorance and misinformation about mRNA Therapies - the tide of hope still hits the shoreline.